Intuitive Surgical (NASDAQ:ISRG) Stock: Insider Craig Barratt Sells 1,150 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Craig Barratt sold 1,150 shares of Intuitive Surgical stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $460.00, for a total value of $529,000.00. Following the sale, the director directly owned 1,150 shares in the company, valued at approximately $529,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Intuitive Surgical Price Performance

ISRG traded down $19.00 on Thursday, reaching $463.10. The company’s stock had a trading volume of 2,238,358 shares, compared to its average volume of 2,444,045. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The business’s 50 day moving average is $406.25 and its 200 day moving average is $432.60. The stock has a market cap of $160.53 billion, a price-to-earnings ratio of 56.00, a price-to-earnings-growth ratio of 3.04 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The business had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The business’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.40 earnings per share. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ISRG. TD Cowen reaffirmed a “buy” rating and issued a $485.00 price target on shares of Intuitive Surgical in a report on Monday, October 19th. Zacks Research upgraded shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 22nd. Truist Financial reduced their target price on shares of Intuitive Surgical from $580.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Barclays restated an “overweight” rating and issued a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Finally, Royal Bank Of Canada decreased their target price on shares of Intuitive Surgical from $575.00 to $550.00 and set an “outperform” rating for the company in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $493.54.

Institutional Trading of Intuitive Surgical

Large investors have recently added to or reduced their stakes in the business. North Point Portfolio Managers Corp OH acquired a new stake in Intuitive Surgical during the 3rd quarter worth about $27,000. John Boyer Inc. acquired a new stake in shares of Intuitive Surgical during the 3rd quarter valued at $27,000. Compass Wealth Management LLC acquired a new position in shares of Intuitive Surgical in the third quarter worth $29,000. Main Street Group LTD purchased a new stake in shares of Intuitive Surgical during the first quarter worth $30,000. Finally, Compass Financial Management LLC purchased a new stake in shares of Intuitive Surgical during the second quarter worth $30,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.